Xiao Fu

2.3k citations
85 papers · 1.6k indexed · h-index 22
Topics
Cancer Immunotherapy and Biomarkers (8 papers)Lung Cancer Research Studies (8 papers)3D Printing in Biomedical Research (7 papers)
Journals
Advanced MaterialsSHILAP Revista de lepidopterologíaPLoS ONE

In The Last Decade

Xiao Fu

78 papers receiving 1.6k citations

Peers

Xiao Fu
Comparison fields: 5 of 130
  • Molecular Biology 430
  • Biomedical Engineering 396
  • Oncology 330
  • Pulmonary and Respiratory Medicine 248
  • Immunology 236
Replace Anvay Ukidve with:
Anvay Ukidve United States
Rui Wu China
Hanze Hu United States
Luis Solorio United States
Qin Wang China
Yi Xiang China
Juliane Nguyen United States
Matthias Bartneck Germany
Smriti Singh Germany
June‐Wha Rhee United States
Xiao Fu relative to Anvay Ukidve United States Anvay Ukidve's profile →
Citations per field
00.5×6.8×
Anvay Ukidve · 1×
Citations per year

Countries citing papers authored by Xiao Fu

Since Specialization
Citations

This map shows the geographic impact of Xiao Fu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiao Fu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiao Fu more than expected).

Fields of papers citing papers by Xiao Fu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiao Fu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiao Fu. The network helps show where Xiao Fu may publish in the future.

Co-authorship network of co-authors of Xiao Fu

This figure shows the co-authorship network connecting the top 25 collaborators of Xiao Fu. A scholar is included among the top collaborators of Xiao Fu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiao Fu. Xiao Fu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 3
2 10
3 16
4 11
5 3
6 0
7 32
8 17
9 5
10 59
11 11
12 22
13 37
14 5
15 7
16 10
17 8
18
Regulation and mechanism of Yiqijianpi compound on gastric motility of the rats with diabetic gastroparesis
2
19 20
20 37

About Xiao Fu

Xiao Fu is a scholar working on Oncology, Molecular Medicine and Cancer Research, having authored 85 papers that have together received 1.6k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (8 papers), Lung Cancer Research Studies (8 papers) and 3D Printing in Biomedical Research (7 papers). The work is most often cited by research in Pharmaceutical Science (171 citations), Cancer Research (190 citations) and Oncology (330 citations). Xiao Fu has collaborated with scholars based in China, United States and Australia. Frequent co-authors include Yuanjin Zhao, Xiaoxuan Zhang, Guopu Chen, Yuetong Wang, Ping Dong, Xiaodong Han, Xiang Chen, Danqing Huang, Tao Tian and Zhiping Ruan. Their work appears in journals such as Advanced Materials, SHILAP Revista de lepidopterología and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026